We are excited to share details with you about an opportunity to learn about using blood-based biomarkers in the evaluation of pulmonary nodules on Friday August 7 at 5:30pm ET. With just a standard blood draw, Nodify Lung™ testing helps reclassify risk of malignancy of nodules by identifying patients with a higher or lower risk than indicated by traditional risk assessment.
The session, presented by Michael Pritchett, DO, MPH, will discuss the challenges with managing indeterminate pulmonary nodules, Dr. Pritchett’s experience with the tests as the Principal Investigator of the ORACLE study, and real-world use of the Nodify Lung testing strategy through case studies and national data. This presentation is sponsored by Biodesix and is open to all ATS 2020 Virtual attendees.
RSS